Erlonat 100 mg Tablet

Erlonat 100 mg tablet is made of Erlotinib, a medication that is used as a targeted therapy in the class of Tyrosine Kinase Inhibitors (TKIs). It is generally prescribed in cases of non-small cell lung cancer (NSCLC) and advanced pancreatic cancer. On websites like Alldaygen, it is listed as an effective, lower-cost alternative to branded cancer medications and provides a more affordable option to customers for advanced cancer care.

How Erlonat 100 mg Works

Erlonat 100 mg specifically targets the Epidermal Growth Factor Receptor (EGFR) protein found on the surface of certain cancer cells. In many cancers, EGFR signals cells to grow and divide uncontrollably. Erlotinib blocks these signals, slowing down or stopping the progression, spread, and proliferation of cancer cells.

• Non-Small Cell Lung Cancer (NSCLC): Used as a first-line treatment, maintenance therapy, or second-line treatment for patients with locally advanced or metastatic NSCLC, especially those harboring specific EGFR gene mutations.

• Pancreatic Cancer: Administered in combination with gemcitabine for patients with advanced or metastatic pancreatic cancer.

Dosage and Administration

Take Erlonat 100 mg orally once daily as prescribed by your oncologist. Erlotinib should be taken on an empty stomach. This means it should be taken at least 1 hour before a meal or 2 hours after a meal. Food alters the absorption of Erlonat and should be avoided when taking Erlonat. Swallow the tablet with a full glass of water. It is important to take Erlonat every day at the same time.

Browse Similar Product and Option: Erlonat 150 mg Tablet

Common Side Effects

While Erlonat is targeted, patients may experience side effects including:

• Skin rash, dry skin, or acne-like eruptions

• Diarrhea and loss of appetite

• Fatigue and general weakness

• Nausea or minor digestive upset

Important Precautions

1. Medical Supervision: Erlonat 100 mg should only be taken under the strict guidance of a qualified oncologist.

2. Smoking: Smoking significantly reduces the plasma concentration of Erlotinib; patients are strongly advised to stop smoking during treatment.

3. Pregnancy & Nursing: Unsafe for pregnant or breastfeeding women, as it poses risks to the fetus. Proper contraception should be maintained during treatment.

Always consult your healthcare provider or oncologist for personalized medical advice regarding Erlonat 100 mg dosage, drug interactions, and potential side effect management.